Ko, E.-J., Suh, D. S., Kim, H., Lee, J. Y., Eo, W. K., Kim, H., Kim, K. H., & Cha, H.-J. (2024). Transcriptome analysis of the effect of HERV-K env gene knockout in ovarian cancer cell lines. Genes & Genomics, 46(11), 1293–1301. https://doi.org/10.1007/s13258-024-01544-4

Song, B. B., Anderson, Z. S., Masjedi, A. D., Lee, M. W., Mandelbaum, R. S., Klar, M., Roman, L. D., Wright, J. D., & Matsuo, K. (2024). Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer. Obstetrics & Gynecology, 144(1), 68–78. https://doi.org/10.1097/aog.0000000000005530

Matsuo, K., Chen, L., Klar, M., Roman, L. D., Sood, A. K., Gershenson, D. M., & Wright, J. D. (2024). Primary Cytoreduction and Survival for Patients With Less-Common Epithelial Ovarian Cancer. JAMA Network Open, 7(6), e2417775. https://doi.org/10.1001/jamanetworkopen.2024.17775

Suzuki, T., Conant, A., Jung, Y., Bax, R., Antonissen, A., Chen, W., Yu, G., Ioffe, Y. J., Wang, C., & Unternaehrer, J. J. (2024). A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance. International Journal of Molecular Sciences, 25(7), 3843. https://doi.org/10.3390/ijms25073843

Huang, Y., Rauh-Hain, J. A., McCoy, T. H., Hou, J. Y., Hillyer, G., Ferris, J. S., Hershman, D., Wright, J. D., & Melamed, A. (2024). Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning. Gynecologic Oncology, 186, 9–16. https://doi.org/10.1016/j.ygyno.2024.03.016

Lee, M. W., Anderson, Z. S., Girma, A. M., Klar, M., Roman, L. D., Carlson, J. W., Wright, J. D., Sood, A. K., & Matsuo, K. (2024). Diagnosis Shift in Site of Origin of Tubo-Ovarian Carcinoma. Obstetrics & Gynecology, 143(5), 660–669. https://doi.org/10.1097/aog.0000000000005562

Kim, D.-Y., Kim, H., Ko, E.-J., Koh, S. B., Kim, H., Lee, J. Y., Lee, C. M., Eo, W. K., Kim, K. H., & Cha, H.-J. (2024). Correlation analysis of cancer stem cell marker CD133 and human endogenous retrovirus (HERV)-K env in SKOV3 ovarian cancer cells. Genes & Genomics, 46(4), 511–518. https://doi.org/10.1007/s13258-024-01499-6

Symecko, H., Schnoll, R., Beidas, R. S., Bekelman, J. E., Blumenthal, D., Bauer, A.-M., Gabriel, P., Boisseau, L., Doucette, A., Powers, J., Cappadocia, J., McKenna, D. B., Richardville, R., Cuff, L., Offer, R., Clement, E. G., Buttenheim, A. M., Asch, D. A., Rendle, K. A., … Domchek, S. M. (2023). Protocol to evaluate sequential electronic health record-based strategies to increase genetic testing for breast and ovarian cancer risk across diverse patient populations in gynecology practices. Implementation Science, 18(1). https://doi.org/10.1186/s13012-023-01308-w

LaRose, M., Manji, G. A., & Bates, S. E. (2024). Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer. Seminars in Oncology, 51(1–2), 36–44. https://doi.org/10.1053/j.seminoncol.2023.11.001

Matsuo, K., Rau, A. R., Ciesielski, K. M., Vallejo, A., Mandelbaum, R. S., Roman, L. D., Klar, M., Matsushima, K., & Wright, J. D. (2023). Concurrent Minimally Invasive Gynecologic Procedures at the Time of Laparoscopic Cholecystectomy. Obstetrics & Gynecology, 142(6), 1491–1495. https://doi.org/10.1097/aog.0000000000005420

Kentros, P. A., Huang, Y., Wylie, B. J., Khoury‐Collado, F., Hou, J. Y., de Meritens, A. B., St. Clair, C. M., Hershman, D. L., & Wright, J. D. (2023). Ambient particulate matter air pollution exposure and ovarian cancer incidence in the USA: An ecological study. BJOG: An International Journal of Obstetrics & Gynaecology, 131(5), 690–698. Portico. https://doi.org/10.1111/1471-0528.17689

Zeng, Y., Arisa, O., Peer, C. J., Fojo, A., & Figg, W. D. (2024). PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. Seminars in Oncology, 51(1–2), 19–24. https://doi.org/10.1053/j.seminoncol.2023.09.005

Ferris, J. S., Morgan, D. A., Tseng, A. S., Terry, M. B., Ottman, R., Hur, C., Wright, J. D., & Genkinger, J. M. (2023). Risk factors for developing both primary breast and primary ovarian cancer: A systematic review. Critical Reviews in Oncology/Hematology, 190, 104081. https://doi.org/10.1016/j.critrevonc.2023.104081

Sun, Y., Liu-Jarin, X., Hamele-Bena, D., Murty, V. V., Clancy, E., & Chen, X. (2022). Ovarian Malignant Mixed Germ Cell Tumor With Prominent Embryoid Bodies (Polyembryoma Background): A Case Report and Literature Review. International Journal of Gynecological Pathology, 42(4), 426–431. https://doi.org/10.1097/pgp.0000000000000905

Matsuo, K., Matsuzaki, S., Maeda, M., Rau, A. R., Yoshihara, K., Tamura, R., Shimada, M., Machida, H., Mikami, M., Klar, M., Roman, L. D., Wright, J. D., Sood, A. K., & Gershenson, D. M. (2023). Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas. JAMA Network Open, 6(6), e2318602. https://doi.org/10.1001/jamanetworkopen.2023.18602

O’Mahony, D. G., Ramus, S. J., Southey, M. C., Meagher, N. S., Hadjisavvas, A., John, E. M., Hamann, U., Imyanitov, E. N., Andrulis, I. L., Sharma, P., Daly, M. B., Hake, C. R., Weitzel, J. N., Jakubowska, A., Godwin, A. K., Arason, A., Bane, A., Simard, J., … Soucy, P. (2023). Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. British Journal of Cancer, 128(12), 2283–2294. https://doi.org/10.1038/s41416-023-02263-5

Matsuo, K., Chen, L., Matsuzaki, S., Mandelbaum, R. S., Ciesielski, K. M., Silva, J. P., Klar, M., Roman, L. D., Accordino, M. K., Melamed, A., Elkin, E., Hershman, D. L., & Wright, J. D. (2023). Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy for Ovarian Cancer Prevention. Annals of Surgery, 277(5), e1116–e1123. https://doi.org/10.1097/sla.0000000000005374

Fu, S., Yao, S., Yuan, Y., Previs, R. A., Elias, A. D., Carvajal, R. D., George, T. J., Yuan, Y., Yu, L., Westin, S. N., Xing, Y., Dumbrava, E. E., Karp, D. D., Piha-Paul, S. A., Tsimberidou, A. M., Ahnert, J. R., Takebe, N., Lu, K., Keyomarsi, K., & Meric-Bernstam, F. (2023). Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of Clinical Oncology, 41(9), 1725–1734. https://doi.org/10.1200/jco.22.00830

Jorgensen, K., Meernik, C., Wu, C.-F., Murphy, C. C., Baker, V. L., Jarmon, P., Brady, P. C., Nitecki, R., Nichols, H. B., & Rauh-Hain, J. A. (2023). Disparities in Fertility-Sparing Treatment and Use of Assisted Reproductive Technology After a Diagnosis of Cervical, Ovarian, or Endometrial Cancer. Obstetrics & Gynecology, 141(2), 341–353. https://doi.org/10.1097/aog.0000000000005044

Matsuo, K., Klar, M., Barakzai, S. K., Jooya, N. D., Nusbaum, D. J., Shimada, M., Roman, L. D., & Wright, J. D. (2022). Utilization of sentinel lymph node biopsy in the early ovarian cancer surgery. Archives of Gynecology and Obstetrics, 307(2), 525–532. https://doi.org/10.1007/s00404-022-06595-0

Hou, J. Y., Chapman, J. S., Kalashnikova, E., Pierson, W., Smith-McCune, K., Pineda, G., Vattakalam, R. M., Ross, A., Mills, M., Suarez, C. J., Davis, T., Edwards, R., Boisen, M., Sawyer, S., Wu, H.-T., Dashner, S., Aushev, V. N., George, G. V., Malhotra, M., … Ford, J. M. (2022). Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecologic Oncology, 167(2), 334–341. https://doi.org/10.1016/j.ygyno.2022.09.004

Huepenbecker, S. P., Wright, J. D., Downer, M. K., Incerti, D., Luhn, P., Dolado, I., Bastiere-Truchot, L., Lin, Y. G., Chan, J. K., & Meyer, L. A. (2022). Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer. Obstetrics & Gynecology, 140(5), 758–767. https://doi.org/10.1097/aog.0000000000004958

Trivedi, M. S., Arber, N., Friedman, E., Garber, J. E., Holcomb, K., Horowitz, N. S., Wright, J. D., Lee, J. J., Vornik, L. A., Abutaseh, S., Castile, T., Sauter, E. R., Dimond, E., Heckman-Stoddard, B. M., House, M., Samimi, G., Brown, P. H., & Crew, K. D. (2022). Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy. Cancer Prevention Research, 15(11), 721–726. https://doi.org/10.1158/1940-6207.capr-22-0051

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147

Karia, P. S., Huang, Y., Tehranifar, P., Visvanathan, K., Wright, J. D., & Genkinger, J. M. (2022). Racial and ethnic differences in the adoption of opportunistic salpingectomy for ovarian cancer prevention in the United States. American Journal of Obstetrics and Gynecology, 227(2), 257.e1-257.e22. https://doi.org/10.1016/j.ajog.2022.04.036

Gamble, C. R., Chen, L., Szamreta, E., Monberg, M., Hershman, D., & Wright, J. (2022). Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. Archives of Gynecology and Obstetrics, 305(6), 1647–1654. https://doi.org/10.1007/s00404-021-06282-6

Guida, F., Dioun, S., Fagotti, A., Melamed, A., Grossi, A., Scambia, G., Wright, J. D., & Tergas, A. I. (2022). Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis. Gynecologic Oncology, 166(1), 181–187. https://doi.org/10.1016/j.ygyno.2022.04.005

Li, S., Silvestri, V., Leslie, G., Rebbeck, T. R., Neuhausen, S. L., Hopper, J. L., Nielsen, H. R., Lee, A., Yang, X., McGuffog, L., Parsons, M. T., Andrulis, I. L., Arnold, N., Belotti, M., Borg, Å., Buecher, B., Buys, S. S., Caputo, S. M., Chung, W. K., … Antoniou, A. C. (2022). Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 40(14), 1529–1541. https://doi.org/10.1200/jco.21.02112

Dareng, E. O., Tyrer, J. P., Barnes, D. R., Jones, M. R., Yang, X., Aben, K. K. H., Adank, M. A., Agata, S., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Aravantinos, G., Arun, B. K., Augustinsson, A., Balmaña, J., Bandera, E. V., Barkardottir, R. B., Barrowdale, D., Beckmann, M. W., … Pharoah, P. D. P. (2022). Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 30(3), 349–362. https://doi.org/10.1038/s41431-021-00987-7